IP Library Granted Patent US 12,434,008
Granted Patent B1
US 12,434,008 · App. 19/063,816 · Granted Oct 7, 2025

Lock ring for a medicament delivery device

Inventors: Alexander Hee-Hanson (Melbourn, GB); Thomas Lever (Melbourn, GB); Michael Parrott (Melbourn, GB); Robert Wilson (Melbourn, GB); Haiming Wu (Cambridge, MA)
Assignee: Genzyme Corporation
A61M5/31571A61M5/31565A61M5/31566
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,434,008
App. No.
19/063,816
Granted
Oct 7, 2025
Kind
B1
Abstract

The application relates to a lock ring for a medicament delivery device. The lock ring comprises a hollow main body formed from a plurality of circumferentially extending portions. Each portion is defined between tool split lines defining circumferential ends of the portions. Each circumferential end of a portion is connected to an adjacent portion along a tool split line. The main body comprises a plurality of bearing elements configured to contact a body of a medicament delivery device. Each of the plurality of bearing elements is configured to form a low friction rotation interface. At least one of the plurality of bearing elements is formed proximate to one of the circumferential ends of a portion of the main body.

Claims (42)

1. A lock ring for a medicament delivery device, the lock ring comprising:

a hollow main body formed from a plurality of circumferentially extending portions, wherein each portion is defined between tool split lines defining circumferential ends of the portions, and each circumferential end of a portion is connected to an adjacent portion along a tool split line,

wherein the main body comprises a plurality of bearing elements configured to contact a body of the medicament delivery device,

wherein each of the plurality of bearing elements is configured to form a low friction rotation interface, and

wherein at least one of the plurality of bearing elements is formed on or proximate to one of the circumferential ends of a portion of the main body.

2. The lock ring according to claim 1 , wherein the at least one of the plurality of bearing elements is formed on at least one of the circumferential ends of one of the portions of the main body such that it forms a part of the circumferential ends.

3. The lock ring according to claim 2 , wherein the at least one of the plurality of bearing elements is formed by a first part and a second part, the first part being formed on a first circumferential end of a first portion of the main body, and the second part being formed on a second circumferential end of a second portion of the main body that is adjacent to the first portion of the main body.

4. The lock ring according to claim 3 , wherein the first and second parts of the at least one of the plurality of bearing elements are formed with reflectional symmetry on adjacent portions of the main body about the tool split line.

5. The lock ring according to claim 3 , wherein each portion of the main body comprises a first part of one of the plurality of bearing elements on its first circumferential end and a second part of one of the plurality of bearing elements on its second circumferential end.

6. The lock ring according to claim 1 , wherein the at least one of the plurality of bearing elements is spaced circumferentially from one of the circumferential end of one of the portions of the main body by an aperture.

7. The lock ring according to claim 6 , wherein a first bearing of the plurality of bearing elements is formed proximate to a first circumferential end of a first portion of the main body and a second bearing element is formed proximate to a first circumferential end of a second portion of the main body.

8. The lock ring according to claim 7 , wherein the first and second bearing elements are formed with rotational symmetry on adjacent portions of the main body about a central longitudinal axis of the main body.

9. The lock ring according to claim 8 , wherein the at least one of the plurality of bearing elements is formed by a circumferentially extending beam.

10. The lock ring according to claim 9 , wherein the circumferentially extending beam is defined by first and second slots extending either side of the beam.

11. The lock ring according to claim 10 , wherein the first and second slots extend generally circumferentially from at least one of the circumferential ends of at least one portion of the main body.

12. The lock ring according to claim 10 , wherein the first and second slots extend perpendicularly to the longitudinal axis of the main body and parallel to each other.

13. The lock ring according to claim 9 , wherein the circumferentially extending beam comprises a radially outwardly extending protrusion.

14. The lock ring according to claim 13 , wherein a circumferential end of the protrusion is located on a free-end of the circumferentially extending beam.

15. The lock ring according to claim 9 , wherein a first section of the circumferential beam is formed in the first portion of the main body, and a second section of the circumferential beam is formed in the second portion of the main body, the first section and the second section of the circumferential beam being merged at the tool split line.

16. The lock ring according to claim 1 , wherein the main body is formed from two circumferentially extending portions.

17. The lock ring according to claim 1 , wherein each of the circumferentially extending portions comprises:

a first section configured to form an outer surface of a medicament delivery device, and

a second section comprising the plurality of bearing elements, the second section being configured to be received within a housing of a medicament delivery device,

wherein the first section comprises a circumferential surface, and

wherein the circumferential surface of the first section of at least one of the portions comprises a planar section configured to indicate a position of the lock ring relative to a medicament delivery device during use.

18. The lock ring according claim 1 , wherein components of the lock ring are an integrally formed monolithic structure.

19. A medicament delivery device comprising:

a lock ring comprising:

a hollow main body formed from a plurality of circumferentially extending portions, wherein each portion is defined between tool split lines defining circumferential ends of the portions, and each circumferential end of a portion is connected to an adjacent portion along a tool split line,

wherein the main body comprises a plurality of bearing elements configured to contact a body of the medicament delivery device,

wherein each of the plurality of bearing elements is configured to form a low friction rotation interface, and

wherein at least one of the plurality of bearing elements is formed on or proximate to one of the circumferential ends of a portion of the main body.

20. A method of forming a lock ring, the method comprising:

positioning a plurality of mould parts to form a lock ring shaped cavity;

providing a material injection port in at least one of the mould parts;

performing a single injection of material into the lock ring shaped cavity to fill the lock ring shaped cavity; and

cooling the material to form the lock ring.

21. A lock ring for a medicament delivery device, the lock ring comprising:

a hollow main body comprising a plurality of bearing elements configured to contact a body of a medicament delivery device,

wherein at least one of the plurality of bearing elements is formed from a circumferential beam defined between first and second slots extending through the main body,

wherein (i) first and second ends of the beam are connected to the main body or (ii) the circumferential beam comprises a free end that is spaced from the main body by an aperture, and

wherein the circumferential beam comprises a radially outward extending protrusion thereon, the protrusion being configured to form a low friction rotation surface and contact an inner surface of a body of a medicament delivery device during use.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2025
From: PA HOLDING LIMITED
To: PA CONSULTING SERVICES LIMITED
Reel/Frame 072504/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2025
From: HEE-HANSON, ALEXANDER; PARROTT, MICHAEL; LEVER, THOMAS; WILSON, ROBERT
To: PA HOLDINGS LIMITED
Reel/Frame 072139/0512 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2025
From: PA CONSULTING SERVICES
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 072139/0623 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2025
From: WU, HAIMING
To: GENZYME CORPORATION
Reel/Frame 072139/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2025
From: SANOFI-AVENTIS DEUTSCHLAND GMBH
To: GENZYME CORPORATION
Reel/Frame 072139/0648 →
References Cited (101)
US 2522961A · William · 1950 [cited by applicant]
US 2633267A · Lebus · 1953 [cited by applicant]
US 3886513A · Smith et al. · 1975 [cited by applicant]
US 4801295A · Spencer · 1989 [cited by applicant]
US 5045062A · Henson · 1991 [cited by applicant]
US 5176275A · Bowie · 1993 [cited by applicant]
US 5328484A · Somers et al. · 1994 [cited by applicant]
US 5396051A · Kuhn et al. · 1995 [cited by applicant]
US 5478316A · Bitdinger et al. · 1995 [cited by applicant]
US 5505324A · Danico · 1996 [cited by applicant]
US 5505706A · Maus et al. · 1996 [cited by applicant]
US 5536917A · Suppelsa et al. · 1996 [cited by applicant]
US 5622274A · Bright · 1997 [cited by applicant]
US 5738658A · Maus et al. · 1998 [cited by applicant]
US 5984899A · D'Alessio et al. · 1999 [cited by applicant]
US 6080461A · Wozniak et al. · 2000 [cited by applicant]
US 6394985B1 · Lin · 2002 [cited by applicant]
US 7762981B2 · Dacquay et al. · 2010 [cited by applicant]
US 7887506B1 · Smolyarov et al. · 2011 [cited by applicant]
US 7918824B2 · Bishop et al. · 2011 [cited by applicant]
US 8133198B2 · Neer · 2012 [cited by applicant]
US 8409138B2 · James · 2013 [cited by examiner]
US 8734394B2 · Adams et al. · 2014 [cited by applicant]
US 9044553B2 · James et al. · 2015 [cited by applicant]
US 9402957B2 · Adams et al. · 2016 [cited by applicant]
US 9474780B2 · Bokvist et al. · 2016 [cited by applicant]
US 9872961B2 · Fourt et al. · 2018 [cited by applicant]
US 10118001B2 · Fourt et al. · 2018 [cited by applicant]
US 10314981B2 · Sampson et al. · 2019 [cited by applicant]
US 10350362B2 · Dennis, Jr. et al. · 2019 [cited by applicant]
US 10363377B2 · Atterbury et al. · 2019 [cited by applicant]
US 11298462B2 · Atterbury et al. · 2022 [cited by applicant]
US 11331432B2 · Holmqvist et al. · 2022 [cited by applicant]
US 11357820B2 · Corvari et al. · 2022 [cited by applicant]
US 11369751B2 · Ruan et al. · 2022 [cited by applicant]
US 11452821B2 · LaFever et al. · 2022 [cited by applicant]
US 20020055712A1 · Neracher · 2002 [cited by applicant]
US 20040039336A1 · Amark et al. · 2004 [cited by applicant]
US 20050101919A1 · Brunnberg · 2005 [cited by applicant]
US 20050273061A1 · Hommann et al. · 2005 [cited by applicant]
US 20060224124A1 · Scherer · 2006 [cited by applicant]
US 20070270777A1 · Dacquay et al. · 2007 [cited by applicant]
US 20080097311A1 · Dacquay et al. · 2008 [cited by applicant]
US 20080097390A1 · Dacquay et al. · 2008 [cited by applicant]
US 20080269692A1 · James · 2008 [cited by examiner]
US 20090036868A1 · Pinedjian et al. · 2009 [cited by applicant]
US 20090281496A1 · Matusch · 2009 [cited by applicant]
US 20100211005A1 · Edwards et al. · 2010 [cited by applicant]
US 20110054414A1 · Shang et al. · 2011 [cited by applicant]
US 20110144594A1 · Sund et al. · 2011 [cited by applicant]
US 20110202011A1 · Wozencroft · 2011 [cited by applicant]
US 20110319813A1 · Kamen et al. · 2011 [cited by applicant]
US 20130237921A1 · Lannan et al. · 2013 [cited by applicant]
US 20130267897A1 · Kemp et al. · 2013 [cited by applicant]
US 20140236076A1 · Marshall et al. · 2014 [cited by applicant]
US 20140249483A1 · Kiilerich et al. · 2014 [cited by applicant]
US 20140263156A1 · Newsom et al. · 2014 [cited by applicant]
US 20140276637A1 · Massey, Jr. · 2014 [cited by applicant]
US 20150246180A1 · Fenlon et al. · 2015 [cited by applicant]
US 20150273162A1 · Holmqvist · 2015 [cited by applicant]
US 20160001015A1 · Kucuk et al. · 2016 [cited by applicant]
US 20160354555A1 · Gibson et al. · 2016 [cited by applicant]
US 20160367763A1 · Tschirren et al. · 2016 [cited by applicant]
US 20170215699A1 · Ouyang et al. · 2017 [cited by applicant]
US 20170216526A1 · Brereton et al. · 2017 [cited by applicant]
US 20170224929A1 · Sampson et al. · 2017 [cited by applicant]
US 20170246403A1 · Cowe et al. · 2017 [cited by applicant]
US 20170361034A1 · Scheller et al. · 2017 [cited by applicant]
US 20180250471A1 · Grimoldby et al. · 2018 [cited by applicant]
US 20180339114A1 · Wendland et al. · 2018 [cited by applicant]
US 20190030249A1 · Gonzalez et al. · 2019 [cited by applicant]
US 20190192785A1 · Wendland et al. · 2019 [cited by applicant]
US 20190366000A1 · Cowe et al. · 2019 [cited by applicant]
US 20200114041A1 · Alas et al. · 2020 [cited by applicant]
US 20200316314A1 · Buri et al. · 2020 [cited by applicant]
US 20210077732A1 · Egelhofer · 2021 [cited by applicant]
US 20210196900A1 · Apply et al. · 2021 [cited by applicant]
US 20220015429A1 · Brown et al. · 2022 [cited by applicant]
US 20220176042A1 · Belisle · 2022 [cited by applicant]
US 20220395640A1 · Schwartzentruber · 2022 [cited by applicant]
US 20230001099A1 · Dunn · 2023 [cited by applicant]
US 20230238105A1 · Schneider et al. · 2023 [cited by applicant]
US 20230347074A1 · Gavin · 2023 [cited by applicant]
US 20240009397A1 · In et al. · 2024 [cited by applicant]
DE 3921747A1 · 1991 [cited by applicant]
EP 3501577A1 · 2019 [cited by applicant]
WO WO2002047746A1 · 2002 [cited by applicant]
WO WO2004058820A2 · 2004 [cited by applicant]
WO WO2004068820A2 · 2004 [cited by applicant]
WO WO2005018629A1 · 2005 [cited by applicant]
WO WO2006003388A2 · 2006 [cited by applicant]
WO WO2006030220A1 · 2006 [cited by applicant]
WO WO2011109205A2 · 2011 [cited by applicant]
WO WO2016081238A1 · 2016 [cited by applicant]
WO WO2019074788A1 · 2019 [cited by applicant]
WO WO2020190529A1 · 2020 [cited by applicant]
Hamers-Casterman et al., “Naturally occurring antibodies devoid of light chains,” Nature, Jun. 3, 1993, 363(6428):446-448. [cited by applicant]
Holt et al., “Domain antibodies: proteins for therapy,” Trends in Biotechnology, Nov. 2003, 21(11):484-490. [cited by applicant]
Muyldermans, “Single domain camel antibodies: current status,” Reviews in Molecular Biotechnology, Jun. 2001, 74(4):277-302. [cited by applicant]
Needle-based injection systems for medical use requirements and test methods, Part 1: Needle injection systems, ISO 11608-1:2014(E), Third Edition, Switzerland, ISO, Dec. 15, 2014, pp. 1-13. [cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Cited By (1)
US 12,623,021